Discover and read the best of Twitter Threads about #IMS2022VR
Most recents (1)
Although we have multiple options to treat myeloma, the number of highly effective drug classes are few and just not enough.
We continue to have an unmet need for relapsed myeloma. We continue to need accelerated approval by the FDA. @Rfonsi1 @NorthTxMSG #IMS2022 #IMS2022VR
1/
We continue to have an unmet need for relapsed myeloma. We continue to need accelerated approval by the FDA. @Rfonsi1 @NorthTxMSG #IMS2022 #IMS2022VR
1/
We also need accelerated approval of multiple drugs of the same class because patients tolerate one better than the other, and sometimes one works better than the other. It is also important to have competition to foster more innovation and to have some effect on price.
2/
2/
The fact we have made so much progress in myeloma does not mean we don’t need more drugs.
Myeloma remains a serious malignancy and we continue to have unmet needs. So I will continue to advocate for rapid approval of new drugs.
3/
Myeloma remains a serious malignancy and we continue to have unmet needs. So I will continue to advocate for rapid approval of new drugs.
3/
